Page 156 - 2018_09-Mondo

E. Grilz et al.
thromboembolism in patients with cancer
in the presence of competing mortality. J
Thromb Haemost. 2015;13(3):390-397.
21. Delgado J, Pereira A, Villamor N, Lopez- Guillermo A, Rozman C. Survival analysis in hematologic malignancies: recommen- dations for clinicians. Haematologica.
2014;99(9):1410-1420.
22. Fine JP, Gray RJ. A Proportional Hazards
Model for the Subdistribution of a Competing Risk. J Am Stat Assoc. 1999; 94(446):496-509.
23. Terbuch A, Posch F, Annerer LM, et al. Long-term cardiovascular complications in stage I seminoma patients. Clin Transl Oncol. 2017;19(11):1400-1408.
24. McGale P, Darby SC, Hall P, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol. 2011;100(2):167-175.
25. Chen PC, Muo CH, Lee YT, Yu YH, Sung FC. Lung cancer and incidence of stroke: a population-based cohort study. Stroke. 2011;42(11):3034-3039.
26. Kuan AS, Teng CJ, Wu HH, et al. Risk of ischemic stroke in patients with ovarian cancer: a nationwide population-based study. BMC Med. 2014;12(1):53.
27. Kuan AS, Chen SC, Yeh CM, et al. Risk of Ischemic Stroke in Patients With Gastric Cancer. Medicine (Baltimore). 2015; 94(37):e1336.
28. Navi BB, Reiner AS, Kamel H, et al. Association between incident cancer and subsequent stroke. Ann Neurol 2015; 77(2):291-300.
29. Zöller B, Ji J, Sundquist J, Sundquist K. Risk of coronary heart disease in patients with cancer: A nationwide follow-up study from Sweden. Eur J Cancer. 2012;48(1):121-128.
30. Zöller B, Ji J, Sundquist J, Sundquist K. Risk of haemorrhagic and ischaemic stroke in patients with cancer: A nationwide follow- up study from Sweden. Eur J Cancer. 2012;48(12):1875-1883.
31. Navi BB, Reiner AS, Kamel H, et al. Risk of Arterial Thromboembolism in Patients With Cancer. J Am Coll Cardiol. 2017;70(8):926-938.
32. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial throm- boembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled tri- als. Acta Oncol. 2010;49(3):287-297.
33. Pantaleo MA, Mandrioli A, Saponara M, et al. Development of coronary artery steno- sis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer. 2012;12(1):231.
34. Sonpavde G, Bellmunt J, Schutz F, Choueiri TK. The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients. Curr Oncol Rep. 2012; 14(4):295-306.
35. Qi W-X, Shen Z, Tang L-N, Yao Y. Risk of arterial thromboembolic events with vas- cular endothelial growth factor receptor tyrosine kinase inhibitors: An up-to-date meta-analysis. Crit Rev Oncol Hematol. 2014;92(2):71-82.
36. Proverbs-Singh T, Chiu SK, Liu Z, et al. Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. J Natl Cancer Inst. 2012;104(23):1837-1840.
37. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008; 26(32):5204-5212.
38. Khorana AA, Carrier M, Garcia DA, Lee AYY. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):81-91.
39. Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis. https://clinicaltrials.gov/ct2/show/NCT022 85738 [Last accessed 9 Oct 2017].
40. Lindhardsen J, Ahlehoff O, Gislason GH, et
al. Initiation and adherence to secondary prevention pharmacotherapy after myocar- dial infarction in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2012;71(9):1496-1501.
41. Brown MT, Bussell JK. Medication Adherence: WHO Cares? Mayo Clin Proc. 2011;86(4):304-314.
42. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99(16):1232-1239.
43. Roe MT, Messenger JC, Weintraub WS, et al. Treatments, Trends, and Outcomes of Acute Myocardial Infarction and Percutaneous Coronary Intervention. J Am Coll Cardiol. 2010;56(4):254-263.
44. Grysiewicz RA, Thomas K, Pandey DK. Epidemiology of ischemic and hemorrhagic stroke: incidence, prevalence, mortality, and risk factors. Neurol Clin. 2008;26(4):871-895, vii.
45. Mellema WW, van der Hoek D, Postmus PE, Smit EF. Retrospective evaluation of thromboembolic events in patients with non-small cell lung cancer treated with platinum-based chemotherapy. Lung Cancer. 2014;86(1):73-77.
46. Reiner AS, Navi BB, DeAngelis LM, Panageas KS. Increased risk of arterial thromboembolism in older men with breast cancer. Breast Cancer Res Treat. 2017;166(3):903-910.
47. Haguet H, Douxfils J, Mullier F, Chatelain C, Graux C, Dogné JM. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new gener- ation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opin Drug Saf. 2017;16(1):5-12.
48. Hultcrantz M, Pfeiffer RM, Björkholm M, et al. Elevated risk of venous but not arterial thrombosis in Waldenström macroglobu- linemia/lymphoplasmacytic lymphoma. J Thromb Haemost. 2014;12(11):1816-1821.
1556
haematologica | 2018; 103(9)